ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
18.67
-0.85 (-4.33%)
At close: Aug 1, 2025, 4:00 PM
18.66
0.00 (-0.03%)
After-hours: Aug 1, 2025, 4:04 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover ArriVent BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $38.38, which forecasts a 105.63% increase in the stock price over the next year. The lowest target is $32 and the highest is $45.
Price Target: $38.38 (+105.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +114.30% | Jul 22, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +76.80% | Jul 10, 2025 |
| Clear Street | Clear Street | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +71.44% | Jun 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $39 → $44 | Buy | Maintains | $39 → $44 | +135.74% | Jun 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +141.09% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
3.76M
EPS This Year
-3.79
from -2.56
EPS Next Year
-3.15
from -3.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 10.6M | 111.3M | ||
| Avg | n/a | 3.8M | 55.0M | ||
| Low | n/a | n/a | 17.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 2,860.9% | ||
| Avg | - | - | 1,363.8% | ||
| Low | - | - | 355.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -0.98 | -0.62 | ||
| Avg | -3.79 | -3.15 | -2.24 | ||
| Low | -4.41 | -4.66 | -3.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.